Company Encyclopedia
View More
name
GENFLEET-B
02595.HK
GenFleet Therapeutics (Shanghai) Inc. operates as a biopharmaceutical company that focuses on developing novel treatment options in the fields of oncology that cover different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases. The company’s products include GFH925, help for the treatment of advanced non-small cell lung cancer, and GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C. The company was incorporated in 2017 and is based in Shanghai, China.
1.272 T
02595.HKMarket value -Rank by Market Cap -/-

Financial Score

24/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking0/53
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE41.40%A
    • Profit Margin-647.20%E
    • Gross Margin80.81%A
  • Growth ScoreB
    • Revenue YoY39.97%A
    • Net Profit YoY-31.41%D
    • Total Assets YoY9.45%B
    • Net Assets YoY-43.61%E
  • Cash ScoreB
    • Cash Flow Margin-15.45%D
    • OCF YoY39.97%A
  • Operating ScoreD
    • Turnover0.18D
  • Debt ScoreE
    • Gearing Ratio422.38%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | GENFLEET-B weakly declines, with new research and development news becoming the biggest variable?

    GENFLEET-B continued to consolidate at a low level yesterday, with extremely conservative capital flow during the session, and the sector's popularity has not seen an increase. The overall news in the innovative drug industry is weak, and the company has not had any new approvals or milestone announcements recently, leading to a natural decline in trading enthusiasm. Technically, indicators such as KDJ and MACD continue to show weakness, with key support lacking strength, and the stock price is testing new low areas for consolidation. The sector's capital is actively defensive, and the inertia of speculation is severely suppressed. It is worth noting that during previous new drug approvals or key cooperation approvals, the intraday trading often shows early movements, becoming the focus of attention in the trading community. Moving forward, it is essential to closely monitor changes in information flow and capital flow. If there is sudden positive news regarding research and development, it could become a watershed moment for short-term risk exposure. In an uncertain environment, market volatility is high. For the short term, it is recommended to maintain a light position and observe. If there is a sudden increase in intraday trading volume along with research and development progress, one can actively follow up on structural adjustment opportunities; otherwise, prioritize risk control

    Technical Forecast·
    HK
    02595
    +0.08%
    Technical Forecast·
    HK
    02595
    +0.08%

    Top 10 HK Stock Losers (12.22)

    JACOBIO-B(01167) fell 13.58%, with a trading turnover 196.1 Million HKD, and a year-to-date rose 516.5%. SEYOND(02665) fell 10.48%, with a trading turnover 7.8 Million HKD, and a year-to-date rose 29%. LAEKNA-B(02105) fell 8.94%, with a trading turnover 60.6 Million HKD, and a year-to-date rose 50.1%.

    Top Gainers & Losers·
    HK
    01167
    +2.56%
    HK
    02665
    +1.05%
    HK
    02105
    -2.23%
    Top Gainers & Losers·
    HK
    01167
    +2.56%
    HK
    02665
    +1.05%
    HK
    02105
    -2.23%

    Understanding the Market | GENFLEET-B turns from decline to rise of over 9%, first patient enrolled in the study of GFH375 combination therapy for advanced solid tumors completed

    GENFLEET-B's stock price turned from decline to increase in the afternoon, with an increase of over 9%. As of the time of publication, the stock price rose by 6.71%, reported at HKD 28.3, with a trading volume of HKD 44.5183 million. The company announced that its KRAS G12D inhibitor GFH375 combination therapy has completed the enrollment of the first patient at Peking University Cancer Hospital, with the study approved by the National Medical Products Administration, involving combination with cetuximab or chemotherapy. The efficacy and safety of GFH375 will be reported at the 2025 ESMO Annual Meeting

    Zhitong·
    HK
    02595
    +0.08%
    Zhitong·
    HK
    02595
    +0.08%

    GENFLEET-B: The first patient has been dosed in the Phase Ib/II study of KRAS G12D inhibitor GFH375 in combination with cetuximab or chemotherapy for the treatment of advanced solid tumors

    GENFLEET-B announced that the first patient has been dosed in the Phase Ib/II study of GFH375 in combination with cetuximab or chemotherapy, targeting KRAS G12D mutant advanced solid tumors. The study received clinical trial approval in September and primarily evaluates the safety, tolerability, and efficacy of the therapy. The monotherapy of GFH375 is expected to enter Phase I/II trials in 2024 and has received FDA Fast Track designation

    Zhitong·
    HK
    02595
    +0.08%
    Zhitong·
    HK
    02595
    +0.08%

    On October 21st, GENFLEET-B issued 13.386 million shares due to the exercise of the over-allotment option

    According to the Zhitong Finance APP, GENFLEET-B announced that it will issue and allocate 13.386 million H shares on October 21, 2025, due to the full exercise of the over-allotment option

    Zhitong·
    HK
    02595
    +0.08%
    Zhitong·
    HK
    02595
    +0.08%
    Posts
    View More

    $GENFLEET-B(02595.HK) The recent Longbridge lottery rate is acceptable 😌

    • 0
    © 2025 Longbridge｜Disclaimer